Close menu




April 12th, 2024 | 07:00 CEST

AI in healthcare with Evotec, Defence Therapeutics, Bayer: Revolutionary advances and medical breakthroughs

  • Biotechnology
  • Pharma
  • AI
Photo credits: pixabay.com

Artificial intelligence (AI) is gaining momentum in the healthcare sector. AI-based systems can use medical databases to save valuable time in research, enabling companies like Defence Therapeutics to go to market faster than others. In oncology research, the Canadian company has just achieved a breakthrough that gives hope to many cancer patients. AI-assisted diagnoses allow diseases to be detected earlier and treated more effectively, leading to improved quality of life for patients. Precision medicine in strong partnership networks is Evotec's focus. The share is particularly popular with hedge fund managers. Analyzing medical images and data in real-time and detecting even the smallest deviations or anomalies is the top priority for Bayer AG in collaboration with Google Cloud. Which companies are convincing investors the most?

time to read: 5 minutes | Author: Juliane Zielonka
ISIN: EVOTEC SE INH O.N. | DE0005664809 , DEFENCE THERAPEUTICS INC | CA24463V1013 , BAYER AG NA O.N. | DE000BAY0017

Table of contents:


    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview

     

    Evotec: Is the growth breakthrough imminent?

    Modern medicine still largely functions according to the "one size fits all" principle. Until recently, drugs and vaccines were mainly tested on men. This has had a detrimental impact on the health outcomes of women worldwide. Scientists assumed that apart from height, weight and reproductive organs, there were no fundamental differences between men's and women's bodies. As a result, many medications are only effective in around 50% of patients.

    Reason enough to take targeted steps towards more precision medicine. With evolutionary (bio)technology. This is the vision of Evotec, which co-founder Manfred Eigen brought to life. Evotec SE is a global drug discovery and development partner in the pharmaceutical and biotechnology industries. The Company develops products in various therapeutic areas, such as neuroscience, metabolic diseases, oncology, respiratory diseases and women's health.

    Medical professionals need to better understand Diseases and their causes. According to the Company presentation, over 30% of the world's population has an increased risk of cancer. Drug safety remains a major concern: 60% fail in Phase I clinical trials.

    Evotec's business model of continuous commercial partnerships in co-creation now seems to be slowly paying off. Currently, the Company cooperates with 500 active partners, with the top 10 partners generating around 38% of Evotec's revenues, 92% are recurring business and 118 of the 500 partners deliver over EUR 1 million in revenues p.a.

    Several hedge funds have recently modified their holdings of Evotec shares. OLD Mission Capital LLC, Mubadala Investment Co PJSC, Optiver Holding B.V. and Quadrant Capital Group LLC acquired new positions or increased their existing positions.

    Defence Therapeutics: Breakthrough in cancer research with promising potential

    Defence Therapeutics has successfully tested a new anti-cancer vaccine called ARM-002TM. It uses the leading anti-cancer molecule AccuTOX® and achieved an 80% complete response in tests on melanoma models when combined with an immune checkpoint inhibitor. Compared to conventional treatments, this vaccine can trigger specific immune responses that fight tumors and provide long-term protection.

    AccuTOX® is based on Accum™ technology. This technology revolutionizes cancer treatment by delivering drugs specifically and efficiently to infected cells. The unique Accum™ technology platform achieves a 10-fold higher rate of drug delivery compared to current solutions. It has a more effective, targeted dosing and is more powerful in the fight against tumors. This medical milestone makes Accum™ a scalable global solution for the treatment of cancer and infectious diseases.

    The Defence Therapeutics researchers also plan to test the vaccine in ovarian and pancreatic cancer. Data Bridge Market Research estimates that the solid tumor market will be worth USD 209.61 billion in 2021. It is expected to grow to USD 901.27 billion by 2029, representing a compound annual growth rate (CAGR) of 20% during the forecast period from 2022 to 2029.

    The experienced management team at Defence Therapeutics has many years of expertise in capital markets, finance, biochemistry, pharmacology, biotechnology and immunology. Dr. Moutih Rafei, Chief Scientific Officer and Director of Defence Therapeutics is an expert in the field of immuno-oncology with extensive experience in T-cell development, stem cell biology, cancer immunotherapy and autoimmune diseases. He has received over 20 awards and recognitions, and his research has led to numerous publications and patents. Dr. Rafei will be available to answer questions from interested investors after his live presentation at the upcoming 11th International Investment Forum on April 17. Click here for the program overview and free registration.

    Joint venture: Bayer and Google Cloud focus on AI in imaging diagnostics for more precise diagnoses

    Bayer AG and Google Cloud announced this week that they are developing an AI platform to help radiologists diagnose patients faster and process cases more efficiently.

    The platform's generative AI detects anomalies in images that radiologists examine and can also retrieve relevant information from the patient's medical history. For example, when a patient comes in for an annual breast cancer screening, the platform can detect current issues, compare the image with previous screenings, and summarize this information. This creates a more comprehensive picture of the patient's data, aiding doctors in diagnosis.

    The goal is to make the information radiologists need easily accessible and relieve them of spending 15 or 20 minutes searching through patient files. Medical image data makes up around 90% of all health data. They are an important tool for diagnosing patients and their diseases.

    Billions of radiological images are captured worldwide every year, increasing the workload for healthcare professionals. Many new AI tools are required to manage this flood of data efficiently. A first test version will be available in the EU and the US later this year. This partnership has the potential to revolutionize healthcare by improving outcomes, reducing costs and increasing the speed of innovation.


    The increasing integration of artificial intelligence (AI) in healthcare promises a revolution in medical care. AI-based systems can use medical databases to save precious time in research, allowing companies like Defence Therapeutics to bring innovative solutions to market faster. A recent breakthrough in oncology research by the Canadian company will be presented live by Chief Scientific Officer Dr. Moutih Rafei to participating investors at the 11th International Investment Forum digital conference. Click here to go to registration. Evotec is commercially diversified with over 500 strong drug discovery partnerships. With a strong pipeline and a proven success model, Evotec appears to be an attractive investment for investors looking for long-term growth. Various hedge funds have increased their stakes in Evotec shares. The collaboration between Bayer and Google Cloud for AI-powered diagnostic imaging promises faster and more accurate diagnosis by radiologists. This partnership has the potential to revolutionize healthcare by improving outcomes, reducing costs and increasing the speed of innovation. Shares in healthcare companies belong in every well-diversified portfolio. All three companies deserve a closer look.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.


    Der Autor

    Juliane Zielonka

    Born in Bielefeld, she studied German, English and psychology. The emergence of the Internet in the early '90s led her from university to training in graphic design and marketing communications. After years of agency work in corporate branding, she switched to publishing and learned her editorial craft at Hubert Burda Media.

    About the author



    Related comments:

    Commented by Juliane Zielonka on May 17th, 2024 | 07:00 CEST

    Almonty, Rheinmetall, Super Micro Computer - Commodity rally for defense and cloud

    • Mining
    • Tungsten
    • AI
    • Defense

    AI and defense stocks are setting the stock market on fire. Investors worldwide seem to have acquired a taste for artificial intelligence and defense. Wall Street is expecting a four-digit price target for Super Micro Computer soon. Rheinmetall is also enjoying full order books. Since the takeover of a Spanish ammunition manufacturer, production has also increased in this segment. Meanwhile, tensions between the largest economies, the USA and China, are growing enormously, which is reason enough for investors to take a look at Almonty Industries. The tungsten producer is on course for growth thanks to the restart of a mine in South Korea. Tungsten is rising in value as the increase in AI, and armaments are directly boosting demand for the rare earth metal. Who will win the stock market race?

    Read

    Commented by Fabian Lorenz on May 16th, 2024 | 08:00 CEST

    Share price shock at Siemens Energy! What are BioNTech and Cardiol Therapeutics doing?

    • Biotechnology
    • Pharma
    • renewableenergies

    The Siemens Energy share has been one of the surprises of recent months. It has more than doubled since the beginning of the year. Is a crash now imminent? Yes, if you believe Bernstein. Their analysts are shocking us with a horror price target. The Cardiol Therapeutics share performed even better than Siemens Energy in 2024. Despite the 150% rally, analysts see upside potential for the cardiovascular disease specialist. Things will get really exciting at the beginning of June when new study results are due. BioNTech, on the other hand, is currently failing to convince analysts. Reactions to the latest quarterly figures were modest.

    Read

    Commented by Stefan Feulner on May 14th, 2024 | 07:30 CEST

    Bayer, Defence Therapeutics, Novavax - Major events

    • Biotechnology
    • Pharma

    The biotechnology sector is still on the move and is currently characterized by a high degree of volatility. For instance, BioNTech, a former star during the pandemic, reported a net loss of EUR 315 million in the first quarter. The Mainz-based biotech now wants to focus more on the development of its cancer drugs due to the slump in demand for COVID-19 vaccines. However, for years, innovative, undiscovered companies have existed in this billion-dollar market that could, with their technologies, become the new high-flyers in the biotech industry.

    Read